Sopris Capital

Sopris Capital is a multi-strategy investment firm headquartered in Miami, Florida, with a deep and growing portfolio of healthcare technology companies. Rather than operating as a single-product brand, Sopris functions as an investment house and corporate brand whose identity is tied to the healthtech companies it owns, combines, and scales. Its public profile centers on acquiring and integrating technology assets that support end-to-end, AI-enabled patient care. The firm's most visible recent move was the acquisition of Blackford Analysis, a pioneer in AI orchestration for medical imaging, from Bayer. Blackford's platform is deployed by leading original equipment manufacturers and hospitals across various world markets. Sopris announced the deal in October 2026 and stated that it was in the process of combining Blackford under one of its top-performing portfolio companies, Azra AI. Blackford was to continue operating as a separate legal entity with operations in Scotland and the United States, serving existing OEM partners and health system customers without disruption. Sopris's portfolio strategy emphasizes healthcare AI. Azra AI is described as a leading healthcare AI platform built to identify, connect, and manage patients with cancer and other complex illnesses across the care journey. By folding Blackford's imaging AI orchestration capabilities into Azra AI, Sopris aims to reinforce its commitment to end-to-end, AI-enabled patient care and to create a broader platform spanning imaging infrastructure and patient management. The firm operates as a private investment company and does not appear to be publicly listed. Its brand equity rests less on consumer recognition and more on its reputation among healthcare technology operators, OEMs, and health systems as a buyer and integrator of specialized AI assets. Sopris Capital's positioning is that of a multi-strategy investor with operational ambitions in healthtech, using acquisitions and portfolio combinations to assemble a connected set of clinical AI capabilities.

Sopris Capital's public history is primarily documented through its investment activity in healthcare technology. The firm is headquartered in Miami, Florida, and describes itself as a multi-strategy investment firm with a deep and growing portfolio of healthcare technology companies. Its brand identity is therefore tied to the companies it acquires and the platform it assembles rather than to a single product line. A defining moment in the firm's recent history came in October 2026, when Sopris Capital announced it had completed the acquisition of Blackford Analysis from Bayer. Blackford, founded in 2010, launched the industry's first AI orchestration platform in 2016 and had become a trusted infrastructure partner for radiology departments seeking to evaluate, deploy, and manage AI imaging applications at scale. Its platform carried a portfolio of more than 130 AI applications from over 45 partner vendors, giving health systems a single, vendor-neutral way to bring best-of-breed AI into the imaging workflow without disrupting existing operations. Sopris stated that it was in the process of combining Blackford under one of its top-performing portfolio companies, Azra AI, with the combination expected to be completed in the coming days or weeks. Blackford was to continue operating as a separate legal entity following the combination, with operations in Scotland and the United States, and to continue serving its existing OEM partners and health system customers with no disruption to current deployments or operations. Sopris indicated that a further announcement would be made once the combination was completed. The strategic logic behind the deal was to strengthen AI orchestration capabilities across Sopris's healthtech portfolio and to reinforce its commitment to end-to-end, AI-enabled patient care. Azra AI, described as a leading healthcare AI platform built to identify, connect, and manage patients with cancer and other complex illnesses across the care journey, would serve as the umbrella for Blackford's imaging AI orchestration capabilities. This combination illustrates Sopris's operating model: acquiring specialized healthcare technology assets and integrating them into larger portfolio platforms to create more comprehensive clinical AI offerings.

• Sopris Capital announced the completion of its acquisition of Blackford Analysis from Bayer and its plan to combine Blackford under portfolio company Azra AI.

Multi-strategy investment firm building an integrated healthcare technology platform through acquisitions and portfolio company combinations, with a focus on AI-enabled patient care.

• 2026.10.09

  Reported2026.10.09

  Sopris Capital completes acquisition of Blackford Analysis from Bayer[1]Sopris Capital Acquires Blackford Analysis, Strengthening AI Orchestration Capabilities Across Its HealthTech Portfolioprnewswire.com

  Sopris Capital announced on Oct 9, 2026 that it has completed the acquisition of Blackford Analysis, an AI orchestration platform for medical imaging, from Bayer. Sopris is in the process of combining Blackford under its portfolio company Azra AI, a step expected to be completed in the coming days/weeks, and Blackford will continue to operate as a separate legal entity with operations in Scotland and the United States.

• 2021.04.29

  Reported2021.04.29

  Gallus Medical Detox completes $4 million equity raise[2]Gallus Medical Detox 完成 400 万美元股权融资prnewswire.com

  Gallus Medical Detox Centers completed a $4 million equity raise to fund the opening of additional clinics.

• 2020.02.12

  Reported2020.02.12

  TapestryCare completes Series A financing[3]TapestryCare完成A轮融资prnewswire.com

  TapestryCare announced the completion of a Series A investment round led by Sopris Capital.

Read more

1. 1Sopris Capital Acquires Blackford Analysis, Strengthening AI Orchestration Capabilities Across Its HealthTech Portfolioprnewswire.com
2. 2Gallus Medical Detox 完成 400 万美元股权融资prnewswire.com
3. 3TapestryCare完成A轮融资prnewswire.com